Edmund Harrigan
Director/Board Member bij ACADIA PHARMACEUTICALS INC.
Vermogen: 1 M $ op 31-03-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Stephen Davis | M | 63 | 10 jaar | |
Julian Baker | M | 57 | 23 jaar | |
Herve Hoppenot | M | 64 | 10 jaar | |
Stéphane Thiroloix | M | - |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | 6 jaar |
Clay Thorp | M | 55 | 22 jaar | |
Jason Brown | M | 37 | 6 jaar | |
Jennifer J. Rhodes | F | 53 | 7 jaar | |
Jonathan Mow | M | 59 | 12 jaar | |
Mark Schneyer | M | 50 | 13 jaar | |
Stephen Biggar | M | 53 | 11 jaar | |
Nancy Hutson | M | 74 | 32 jaar | |
James Daly | M | 63 | 8 jaar | |
Susanne Antonie Schaffert | M | 57 | 2 jaar | |
Susan Arnold | M | 49 | 14 jaar | |
Joseph Echevarria | M | 66 | 9 jaar | |
Albert Kildani | M | - | 1 jaar | |
Alex Sapir | M | 57 | 4 jaar | |
Katherine High | M | 72 | 4 jaar | |
Bob Mischler | M | - | 9 jaar | |
Scott A. Byrd | M | 54 |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | - |
Kristopher Hanson | M | 52 | 5 jaar | |
Elizabeth Garofalo | M | 66 | 4 jaar | |
Lawrence Perkins | M | 47 | 2 jaar | |
Brendan Teehan | M | 56 | 6 jaar | |
Julie Fisher | F | - | 6 jaar | |
Thomas Tray | M | 46 | 19 jaar | |
Pablo Cagnoni | M | 60 | 1 jaar | |
Sheila Denton | F | 58 | 1 jaar | |
Katherine Bishop | M | 58 | 3 jaar | |
Jacqualyn Fouse | M | 62 | 7 jaar | |
Sally Susman | F | 62 | 17 jaar | |
Jean-Jacques Bienaimé | M | 70 | 9 jaar | |
Shantanu Narayen | M | 60 | 11 jaar | |
Otis Brawley | M | 64 | 3 jaar | |
Don Soland | M | 65 | 9 jaar | |
Helen Hobbs | M | 71 | 13 jaar | |
Laura Brege | F | 66 | 16 jaar | |
Olivier Jean Bohuon | M | 65 |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | 6 jaar |
William Humphries | M | 57 | 3 jaar | |
Jim Smith | M | 64 | 10 jaar | |
Suzanne Johnson | F | 66 | 17 jaar | |
Paul Clancy | M | 62 | 9 jaar | |
Richard van den Broek | M | 57 | 5 jaar | |
Thibaut Roulon | M | - |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | - |
Benir Ruano | M | - | 2 jaar | |
Denise Brashear | F | - | 2 jaar | |
Kevin Oliver | M | - | 1 jaar | |
Sanjeev Pathak | M | - | 3 jaar | |
Holly Valdiviez | F | - | 2 jaar | |
Kimberly Manhard | F | 64 | - | |
Barbara Dalton | M | 69 | 17 jaar | |
Adora Ndu | M | 43 | 2 jaar | |
Keith Mikkelson | M | - | 22 jaar | |
Mikael Dolsten | M | 65 | 15 jaar | |
James Kihara | M | - | 4 jaar | |
Benjamin J. Strain | M | - | 1 jaar | |
Parag V. Meswani | M | - | 2 jaar | |
Ponni Subbiah | M | - | 5 jaar | |
Claire Poulard | F | - |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | - |
Hugues le Bret | M | - |
Algotherapeutix SAS
Algotherapeutix SAS Medical SpecialtiesHealth Technology AlgoTherapeutix SAS is a clinical-stage biotechnology company based in Suresnes, France. The French company is focused on developing targeted, first-in-class therapeutics for peripheral neuropathic pain. Its lead asset, ATX01, is a proprietary topical formulation of amitriptyline that targets the signaling pathways involved in the regulation of pain by inhibiting specific nociceptive sodium channel receptors. The company is currently recruiting patients for a phase II clinical trial of 240 patients for chemotherapy-induced neuropathic pain and a phase II proof of concept trial for erythromelalgia. AlgoTherapeutix has secured FDA fast track development status and orphan drug designation in both the US and EU. AlgoTherapeutix has raised EUR 35 million to date and has a consortium of investors, including Relyens Innovation Santé/Turenne Capital, UI Investissement, and angel investors. The company was founded in 2018 by Olivier Jean Bohuon and Stéphane Thiroloix, with Stéphane Thiroloix serving as the CEO since 2018. | 5 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Steven Paul | M | 73 | 6 jaar | |
Eric Elenko | M | 51 | 10 jaar | |
Henry McKinnell | M | 81 | 8 jaar | |
William Steere | M | 87 | 28 jaar | |
Jeffrey Kindler | M | 68 | 8 jaar | |
Elena Ridloff | F | 44 | 3 jaar | |
Atul Pande | M | 69 | 8 jaar | |
Alan Musso | M | 61 | 4 jaar | |
Paul Friedman | M | 81 | 20 jaar | |
Dennis Ausiello | M | 78 | 13 jaar | |
David Shedlarz | M | 75 | 31 jaar | |
Christopher Coughlin | M | 71 | 4 jaar | |
George A. Lorch | M | 82 | 15 jaar | |
Amy Schulman | F | 63 | 6 jaar | |
Todd Young | M | 52 | 2 jaar | |
Jacob M. Plotsker | M | 56 | 16 jaar | |
David Wheadon | M | 66 | 4 jaar | |
Paul Trower | M | 54 | 18 jaar | |
Gregory S. Naeve | M | 60 | 8 jaar | |
Yi Ning Zhao | M | 53 | 8 jaar | |
David M. Spencer | M | 61 | 15 jaar | |
Peter Klein | M | 46 | 12 jaar | |
Bibhash Mukhopadhyay | M | 43 | 2 jaar | |
Torsten Erik Rasmussen | M | 78 | 17 jaar | |
Shane Ward | M | 49 | 2 jaar | |
Linda Tufts | F | 70 | 1 jaar | |
Olivier Brandicourt | M | 68 | 13 jaar | |
Frank B. McGuyer | M | 72 | 9 jaar | |
John P. Sharp | M | 59 | 6 jaar | |
John Mascotte | M | 84 | 4 jaar | |
Heather Elizabeth Preston | M | 58 | 2 jaar | |
Caroline Loewy | F | 58 | 5 jaar | |
William McDowall Wells | M | 63 | 4 jaar | |
Michael T. Borer | M | 65 | 11 jaar | |
James Healy | M | 58 | 5 jaar | |
Stephen W. Sanger | M | 78 | 9 jaar | |
M. Anthony Burns | M | 81 | 25 jaar | |
William Herbert Gray | M | 82 | 13 jaar | |
Laurie Olson | F | 61 | 4 jaar | |
Mia Kelley | F | - | 4 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 94 | 94.00% |
Frankrijk | 6 | 6.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Edmund Harrigan
- Persoonlijk netwerk